سوق ارتفاع ضغط الدم العالمي - اتجاهات الصناعة والتوقعات حتى عام 2030

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL HYPERTENSION MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL HYPERTENSION MARKET SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 GLOBAL HYPERTENSION MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 CHALLENGES

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

5.1 PESTEL ANALYSIS

5.2 PORTER’S FIVE FORCES MODEL

6 INDUSTRY INSIGHTS

6.1 MICRO AND MACRO ECONOMIC FACTORS

6.2 PENETRATION AND GROWTH PROSPECT MAPPING

6.3 KEY PRICING STRATEGIES

6.4 INTERVIEWS WITH SPECIALIST

6.5 ANALYIS AND RECOMMENDATION

7 INTELLECTUAL PROPERTY (IP) PORTFOLIO

7.1 PATENT QUALITY AND STRENGTH

7.2 PATENT FAMILIES

7.3 LICENSING AND COLLABORATIONS

7.4 COMPETITIVE LANDSCAPE

7.5 IP STRATEGY AND MANAGEMENT

7.6 OTHER

8 COST ANALYSIS BREAKDOWN

9 TECHNONLOGY ROADMAP

10 INNOVATION TRACKER AND STRATEGIC ANALYSIS

10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS

10.1.1 JOINT VENTURES

10.1.2 MERGERS AND ACQUISITIONS

10.1.3 LICENSING AND PARTNERSHIP

10.1.4 TECHNOLOGY COLLABORATIONS

10.1.5 STRATEGIC DIVESTMENTS

10.2 NUMBER OF PRODUCTS IN DEVELOPMENT

10.3 STAGE OF DEVELOPMENT

10.4 TIMELINES AND MILESTONES

10.5 INNOVATION STRATEGIES AND METHODOLOGIES

10.6 RISK ASSESSMENT AND MITIGATION

10.7 MERGERS AND ACQUISITIONS

10.8 FUTURE OUTLOOK

11 EPIDEMIOLOGY

11.1 INCIDENCE OF ALL BY GENDER

11.2 TREATMENT RATE

11.3 MORTALITY RATE

11.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL

11.5 PATIENT TREATMENT SUCCESS RATES

12 REGULATORY COMPLIANCE

12.1 REGULATORY AUTHORITIES

12.2 REGULATORY CLASSIFICATIONS

12.2.1 CLASS I

12.2.2 CLASS II

12.2.3 CLASS III

12.3 REGULATORY SUBMISSIONS

12.4 INTERNATIONAL HARMONIZATION

12.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS

12.6 REGULATORY CHALLENGES AND STRATEGIES

13 PIPELINE ANALYSIS

13.1 CLINICAL TRIALS AND PHASE ANALYSIS

13.2 DRUG THERAPY PIPELINE

13.3 PHASE III CANDIDATES

13.4 PHASE II CANDIDATES

13.5 PHASE I CANDIDATES

13.6 OTHERS (PRE-CLINICAL AND RESEARCH)

TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR HYPERTENSION MARKET

Company Name Product Name

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE FOR HYPERTENSION MARKET

Phase Number of Projects

Preclinical/Research Projects XX

Clinical Development XX

Phase I XX

Phase II XX

Phase III XX

U.S. Filed/Approved but Not Yet Marketed XX

Total XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE FOR HYPERTENSION MARKET

Therapeutic Area Preclinical/ Research Project

XX XX

XX XX

XX XX

XX XX

XX XX

Total Projects XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE FOR HYPERTENSION MARKET

Technology Preclinical/ Research Project

XX XX

XX XX

XX XX

XX XX

XX XX

Total Projects XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR HYPERTENSION MARKET

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

14 REIMBURSEMENT FRAMEWORK

15 OPPUTUNITY MAP ANALYSIS

16 VALUE CHAIN ANALYSIS

17 HEALTHCARE ECONOMY

17.1 HEALTHCARE EXPENDITURE

17.2 CAPITAL EXPENDITURE

17.3 CAPEX TRENDS

17.4 CAPEX ALLOCATION

17.5 FUNDING SOURCES

17.6 INDUSTRY BENCHMARKS

17.7 GDP RATION IN OVERALL GDP

17.8 HEALTHCARE SYSTEM STRUCTURE

17.9 GOVERNMENT POLICIES

18 GLOBAL HYPERTENSION MARKET, BY TYPE

18.1 OVERVIEW

18.2 PRIMARY HYPERTENSION

18.3 SECONDRY HYPERTENSION

18.3.1 PULMONARY HYPERTENSION

18.3.1.1. GROUP1

18.3.1.2. GROUP 2

18.3.1.3. GROUP 3

18.3.1.4. GROUP 4

18.3.1.5. GROUP 5

18.3.2 SYTEMIC HYPERTENSION

18.3.2.1. NORMAL BLOOD PRESSURE

18.3.2.2. ELEVATED BLOOD PRESSURE

18.3.2.3. STAGE 1 HYPERTENSION

18.3.2.4. STAGE 2 HYPERTENSION

18.3.3 HYPERTENSION DURING PRAGNENVCY

18.3.3.1. GESTATIONAL HYPERTENSION

18.3.3.2. CHRONIC HYPERTENSION

18.3.3.3. PREECLAMPSIA

18.3.3.4. POSTPARTUM PREECLAMPSIA

18.3.3.5. OTHERS

18.4 OTHERS

18.4.1 MALIGNANT HYPERTENSION

18.4.2 ISOLATED SYSTOLIC HYPERTENSION

18.4.3 RESISTANT HYPERTENSION

18.4.4 OPTHALMIC HYPERTENSION

19 GLOBAL HYPERTENSION MARKET, BY TREATMENT

19.1 OVERVIEW

19.2 MARKETED MEDICATION

19.2.1 ACE INHIBITORS

19.2.1.1. BRANDED

19.2.1.1.1. LOTENSIN

19.2.1.1.2. EPANED AND VASOTEC

19.2.1.1.3. PRINIVIL, QBRELIS, AND ZESTRIL

19.2.1.1.4. ACCUPRIL

19.2.1.1.5. ALTACE

19.2.1.2. GENERICS

19.2.1.2.1. BENZAPRIL

19.2.1.2.2. CAPTOPRIL

19.2.1.2.3. ENALAPRIL

19.2.1.2.4. FOSINOPRIL

19.2.1.2.5. LISINOPRIL

19.2.1.2.6. MOEXIPRIL

19.2.1.2.7. PERINDOPRIL

19.2.1.2.8. QUINAPRIL

19.2.1.2.9. RAMIPRIL

19.2.1.2.10. TRANDOLAPRIL

19.2.1.2.11. OTHERS

19.2.2 BETA-BLOCKERS

19.2.2.1. BRANDED

19.2.2.1.1. TENORMIN

19.2.2.1.2. COREG

19.2.2.1.3. COREG CR

19.2.2.1.4. TRANDATE

19.2.2.1.5. KAPSPARGO SPRINKLE AND TOPROL-XL

19.2.2.1.6. LOPRESSOR

19.2.2.1.7. CORGARD

19.2.2.1.8. BYSTOLIC

19.2.2.1.9. INDERAL, INDERAL LA, AND INNOPRAN XL

19.2.2.1.10. OTHERS

19.2.2.2. GENERICS

19.2.2.2.1. ACEBUTOLOL

19.2.2.2.2. ATENOLOL

19.2.2.2.3. BETAXOLOL

19.2.2.2.4. BISOPROLOL

19.2.2.2.5. CARVEDILOL

19.2.2.2.6. LABETALOL

19.2.2.2.7. METOPROLOL SUCCINATE

19.2.2.2.8. METOPROLOL TARTRATE

19.2.2.2.9. NADOLOL

19.2.2.2.10. NEBIVOLOL

19.2.2.2.11. PINDOLOL

19.2.2.2.12. PROPRANOLOL

19.2.2.2.13. TIMOLOL

19.2.2.2.14. CARVEDILOL PHOSPHATE

19.2.2.2.15. OTHERS

19.2.3 CALCIUM CHANNEL BLOCKERS

19.2.3.1. BRANDED

19.2.3.1.1. KATERZIA

19.2.3.1.2. NORVASC

19.2.3.1.3. CARDIZEM CD, CARDIZEM LA, CARTIA XT, DILTZAC, TIAZAC, AND TAZTIA XT

19.2.3.1.4. CONJUPRI

19.2.3.1.5. ADALAT CC AND PROCARDIA X

19.2.3.1.6. CALAN SR, VERELAN, AND VERELAN PM

19.2.3.1.7. SULAR

19.2.3.1.8. OTHERS

19.2.3.2. GENERICS

19.2.3.2.1. AMLODIPINE BENZOATE

19.2.3.2.2. AMLODIPINE BESYLATE

19.2.3.2.3. DILTIAZEM

19.2.3.2.4. FELODIPINE

19.2.3.2.5. ISRADIPINE

19.2.3.2.6. LEVAMLODIPINE

19.2.3.2.7. VERAPAMIL

19.2.3.2.8. NISOLDIPINE

19.2.3.2.9. NIFEDIPINE

19.2.3.2.10. OTHERS

19.2.4 PERIPHERALLY ACTING ALPHA-ADRENERGIC BLOCKERS

19.2.4.1. BY TYPE

19.2.4.1.1. TERAZOSIN

19.2.4.1.2. PRAZOSIN

19.2.4.1.3. DOXAZOSIN

19.2.4.1.4. PHENOXYBENZAMINE

19.2.4.1.5. OTHERS

19.2.4.2. BY DRUG TYPE

19.2.4.2.1. BRANDED

19.2.4.2.1.1 CARDURA AND CARDURA XL

19.2.4.2.1.2 MINIPRESS

19.2.4.2.1.3 HYTRIN

19.2.4.2.1.4 OTHERS

19.2.4.2.2. GENERICS

19.2.5 VASODILATORS

19.2.5.1. BY TYPE

19.2.5.1.1. MINOXIDIL

19.2.5.1.2. HYDRALAZINE

19.2.5.1.3. OTHERS

19.2.5.2. BY DRUG TYPE

19.2.5.2.1. BRANDED

19.2.5.2.2. GENERICS

19.2.6 CENTRALLY-ACTING ALPHA ADRENERGICS

19.2.6.1. BRANDED

19.2.6.1.1. CATAPRES–TTS-1, TTS-2, TTS-3

19.2.6.1.2. CATAPRES

19.2.6.1.3. OTHERS

19.2.6.2. GENERICS

19.2.6.2.1. CLONIDINE

19.2.6.2.2. GUANFACINE

19.2.6.2.3. OTHERS

19.2.7 ANGIOTENSION II RECEPTOR BLOCKERS

19.2.7.1. BRANDED

19.2.7.1.1. EDARBI

19.2.7.1.2. ATACAND

19.2.7.1.3. AVAPRO

19.2.7.1.4. COZAAR

19.2.7.1.5. BENICAR

19.2.7.1.6. MICARDIS

19.2.7.1.7. DIOVAN

19.2.7.1.8. OTHERS

19.2.7.2. GENERICS

19.2.7.2.1. AZILSARTAN

19.2.7.2.2. CANDESARTAN

19.2.7.2.3. OLMESARTAN

19.2.7.2.4. IRBESARTAN

19.2.7.2.5. LOSARTAN

19.2.7.2.6. CANDESARTAN

19.2.7.2.7. TELMISARTAN

19.2.7.2.8. VALSARTAN

19.2.7.2.9. OTHERS

19.2.8 RENIN INHIBITORS

19.2.8.1. BRANDED

19.2.8.1.1. TEKTURNA

19.2.8.1.2. OTHERS

19.2.8.2. GENERICS

19.2.8.2.1. ALISKIREN

19.2.8.2.2. OTEHRS

19.2.9 COMBINATION MEDICINES

19.2.9.1. BRANDED

19.2.9.1.1. TEKTURNA HCT

19.2.9.1.2. EXFORGE

19.2.9.1.3. LOTREL

19.2.9.1.4. AZOR

19.2.9.1.5. TWYNSTA

19.2.9.1.6. EXFORGE HCT

19.2.9.1.7. TENORETIC 50, TENORETIC 100

19.2.9.1.8. LOTENSIN HCT

19.2.9.1.9. ATACAND HCT

19.2.9.1.10. VASERETIC

19.2.9.1.11. ZESTORETIC

19.2.9.1.12. BENICAR HCT

19.2.9.1.13. ACCURETIC AND QUINARETIC

19.2.9.1.14. MICARDIS HCT

19.2.9.1.15. ZIAC

19.2.9.1.16. HYZAAR

19.2.9.1.17. TRIBENZOR

19.2.9.1.18. TARKA

19.2.9.1.19. DIOVAN HCT

19.2.9.1.20. EDARBYCLOR

19.2.9.1.21. DUTOPROL

19.2.9.1.22. LOPRESSOR HCT

19.2.9.1.23. PRESTALIA

19.2.9.1.24. AVALIDE

19.2.9.1.25. OTHERS

19.2.9.2. GENERICS

19.2.9.2.1. ALISKIREN AND HYDROCHLOROTHIAZIDE

19.2.9.2.2. AMLODIPINE BESYLATE AND VALSARTAN

19.2.9.2.3. AMLODIPINE BESYLATE AND BENAZEPRIL

19.2.9.2.4. AMLODIPINE BESYLATE AND OLMESARTAN

19.2.9.2.5. AMLODIPINE BESYLATE AND PERINDOPRIL

19.2.9.2.6. AMLODIPINE BESYLATE AND TELMISARTAN

19.2.9.2.7. AMLODIPINE BESYLATE, HYDROCHLOROTHIAZIDE, AND VALSARTAN

19.2.9.2.8. ATENOLOL AND CHLORTHALIDONE

19.2.9.2.9. BENAZEPRIL AND HYDROCHLOROTHIAZIDE

19.2.9.2.10. CANDESARTAN AND HYDROCHLOROTHIAZIDE

19.2.9.2.11. CAPTOPRIL AND HYDROCHLOROTHIAZIDE

19.2.9.2.12. ENALAPRIL AND HYDROCHLOROTHIAZIDE

19.2.9.2.13. FOSINOPRIL AND HYDROCHLOROTHIAZIDE

19.2.9.2.14. HYDROCHLOROTHIAZIDE AND IRBESARTAN

19.2.9.2.15. HYDROCHLOROTHIAZIDE AND LISINOPRIL

19.2.9.2.16. HYDROCHLOROTHIAZIDE AND METOPROLOL SUCCINATE

19.2.9.2.17. HYDROCHLOROTHIAZIDE AND METOPROLOL TARTRATE

19.2.9.2.18. HYDROCHLOROTHIAZIDE AND OLMESARTAN

19.2.9.2.19. HYDROCHLOROTHIAZIDE AND QUINAPRIL

19.2.9.2.20. HYDROCHLOROTHIAZIDE AND TELMISARTAN

19.2.9.2.21. BISOPROLOL AND HYDROCHLOROTHIAZIDE

19.2.9.2.22. HYDROCHLOROTHIAZIDE AND LOSARTAN

19.2.9.2.23. HYDROCHLOROTHIAZIDE AND METOPROLOL TARTRATE

19.2.9.2.24. HYDROCHLOROTHIAZIDE AND MOEXIPRIL

19.2.9.2.25. AMLODIPINE BESYLATE, HYDROCHLOROTHIAZIDE, AND OLMESARTAN

19.2.9.2.26. TRANDOLAPRIL AND VERAPAMIL

19.2.9.2.27. HYDROCHLOROTHIAZIDE AND VALSARTAN

19.2.9.2.28. CHLORTHALIDONE AND ZILSARTAN

19.2.9.2.29. OTHERS

19.2.10 DIURETICS (SOMETIMES CALLED "WATER PILLS")

19.2.10.1. BY TYPE

19.2.10.1.1. THIAZIDE DIURETICS

19.2.10.1.1.1 LASIX

19.2.10.1.1.2 OTHERS

19.2.10.1.2. CHLORTHALIDONE

19.2.10.1.2.1 HYDROCHLOROTHIAZIDE

19.2.10.1.2.2 INDAPAMIDE

19.2.10.1.2.3 METOLAZONE

19.2.10.1.2.4 OTHERS

19.2.10.1.3. POTASSIUM-SPARING DIURETICS

19.2.10.1.3.1 AMILORIDE HYDROCHLORIDE

19.2.10.1.3.2 SPIRONOLACTONE

19.2.10.1.3.3 TRIAMTERENE

19.2.10.1.3.4 EPLERENONE

19.2.10.1.3.5 OTHERS

19.2.10.1.4. LOOP DIURETIC

19.2.10.1.4.1 FUROSEMIDE

19.2.10.1.4.2 BUMETANIDE

19.2.10.1.4.3 TORSEMIDE

19.2.10.1.4.4 OTHERS

19.2.10.1.5. COMBINATION DIURETICS

19.2.10.1.5.1 AMILORIDE HYDROCHLORIDE + HYDROCHLOROTHIAZIDE

19.2.10.1.5.2 SPIRONOLACTONE + HYDROCHLOROTHIAZIDE

19.2.10.1.5.3 TRIAMTERENE + HYDROCHLOROTHIAZIDE

19.2.10.1.5.4 OTHERS

19.2.10.2. BY DRUG TYPE

19.2.10.2.1. BRANDED

19.2.10.2.1.1 DIURIL

19.2.10.2.1.2 MIDAMOR

19.2.10.2.1.3 INSPRA

19.2.10.2.1.4 LASIX

19.2.10.2.1.5 MICROZIDE

19.2.10.2.1.6 ALDACTAZIDE

19.2.10.2.1.6.1. DYAZIDE, MAXZIDE, AND MAXZIDE-25

19.2.10.2.1.7 ALDACTONE AND CAROSPIR

19.2.10.2.1.8 DEMADEX

19.2.10.2.1.9 ZAROXOLYN

19.2.10.2.1.10 LOZOL

19.2.10.2.1.11 NATRILIX

19.2.10.2.1.12 INDIPAM

19.2.10.2.1.13 OTHERS

19.2.10.2.2. GENERICS

19.2.10.2.2.1 HYDROCHLOROTHIAZIDE

19.2.10.2.2.2 CHLOROTHIAZIDE

19.2.10.2.2.3 CHLORTHALIDONE

19.2.10.2.2.4 AMILORIDE AND HYDROCHLOROTHIAZIDE

19.2.10.2.2.5 FUROSEMIDE

19.2.10.2.2.6 EPLERENONE

19.2.10.2.2.7 HYDROCHLOROTHIAZIDE AND SPIRONOLACTONE

19.2.10.2.2.8 HYDROCHLOROTHIAZIDE AND TRIAMTERENE

19.2.10.2.2.9 INDAPAMIDE

19.2.10.2.2.10 SPIRONOLACTONE

19.2.10.2.2.11 TORSEMIDE

19.2.10.2.2.12 METOLAZONE

19.2.10.2.2.13 OTHERS

19.3 PIPELINE MEDICATION

19.3.1 LORUNDROSTAT

19.3.2 ZILEBESIRAN

19.3.3 ION904

19.3.4 L606

19.3.5 AV-101

19.3.6 CS585

19.3.7 TREPROSTINIL PALMITIL INHALATION POWDER

19.3.8 SERALUTINIB (GB002)

19.3.9 GMA301

19.3.10 RT-234- PAH

19.3.11 ABI-009

19.3.12 PAXTRAVA

19.3.13 TAFLUPROST / TIMOLOL MALEATE

19.3.14 QGC001

19.4 ADDITIONAL THERAPY

19.4.1 MONOTHERAPY

19.4.2 COMBINATION THERAPY

19.4.3 TRIPLE THERAPY

19.4.4 OTHERS

19.5 HERBAL SUPPLEMENT

19.5.1 AGED GARLIC EXTRACT

19.5.2 BEETROOT JUICE

19.5.3 COCOA FLAVONOIDS

19.5.4 KING OF BITTER

19.5.5 CELERY SEED EXTRACT

19.5.6 CHINESE GOLDTHREAD

19.5.7 SAFFRON

19.5.8 HIBISCUS

19.5.9 BLACK CUMIN

19.5.10 GINGER

19.5.11 CORIANDER

19.6 OTHERS

19.6.1 CARUM COPTICUM

19.6.2 TRIBULUS TERRESTRIS

19.6.3 NIGELLA SATIVA

19.6.4 BLACK JACK

19.6.5 BLACK PLUM

19.6.6 BURDOCK

19.6.7 OTHERS

20 GLOBAL HYPERTENSION MARKET, BY MODE OF PURCHASE

20.1 OVERVIEW

20.2 PRESCRIPTION DRUGS

20.2.1 BETA-BLOCKERS

20.2.2 ACE INHIBITORS

20.2.3 ANGIOTENSIN II RECEPTOR BLOCKERS

20.2.4 CALCIUM CHANNEL BLOCKERS

20.2.5 ALPHA BLOCKERS

20.2.6 ALPHA-2 RECEPTOR AGONISTS

20.2.7 COMBINED ALPHA AND BETA-BLOCKERS

20.2.8 VASODILATORS

20.2.9 OTHERS

20.3 OVER THE COUNTER

20.3.1 DIURETIC

20.3.2 OTHERS

21 GLOBAL HYPERTENSION MARKET, BY DRUG TYPE

21.1 OVERVIEW

21.2 BRANDED

21.2.1 TEVETEN

21.2.2 AVAPRO

21.2.3 DIOVAN

21.2.4 CARDIZEM

21.2.5 PROCARDIA XL

21.2.6 CALAN SR

21.2.7 SECTRAL

21.2.8 TENORMIN

21.2.9 INDERAL

21.2.10 CARDURA

21.2.11 MINIPRESS

21.2.12 HYTRIN

21.2.13 ALDOMET

21.2.14 CATAPRES

21.2.15 WYTENSIN

21.2.16 TENEX

21.2.17 COREG

21.2.18 APRESOLINE

21.2.19 LONITEN

21.2.20 LOZOL

21.2.21 NATRILIX

21.2.22 INDIPAM

21.2.23 OTHERS

21.3 GENERICS

22 GLOBAL HYPERTENSION MARKET, BY ROUTE OF ADMINISTRATION

22.1 OVERVIEW

22.2 ORAL

22.2.1 TABLETS

22.2.2 CAPSULES

22.2.3 ORAL SUSPENSION

22.3 PARENTERAL

22.3.1 INTRAVENOUS

22.3.2 SUBCUTANEOUS

22.3.3 INTRAMUSCULAR

22.3.4 OTHERS

22.4 TOPICAL

22.4.1 OINTMENTS

22.4.2 PATCHES

22.5 INHALATION

22.6 OTHERS

23 GLOBAL HYPERTENSION MARKET, BY AGE GROUP

23.1 OVERVIEW

23.2 PEDIATRIC

23.2.1 MALE

23.2.2 FEMALE

23.3 ADULT

23.3.1 MALE

23.3.2 FEMALE

23.4 GERIATRIC

23.4.1 MALE

23.4.2 FEMALE

24 GLOBAL HYPERTENSION MARKET, BY END USER

24.1 OVERVIEW

24.2 HOSPITALS

24.2.1 PUBLIC

24.2.2 PRIVATE

24.3 SPECIALTY CLINICS

24.3.1 PUBLIC

24.3.2 PRIVATE

24.4 ACADEMIC AND RESEARCH CENTRES

24.5 HOME HEALTHCARE

24.6 OTHERS

25 GLOBAL HYPERTENSION MARKET, BY DISTRIBUTION CHANNEL

25.1 OVERVIEW

25.2 DIRECT TENDER

25.3 RETAIL SALES

25.3.1 ONLINE

25.3.1.1. COMPANY WEBSITE

25.3.1.2. E-STORES

25.3.1.3. OTHERS

25.3.2 OFFLINE

25.3.2.1. HOSPITAL PHARMACY

25.3.2.2. MEDICINE STORES

25.3.2.3. OTHERS

25.4 OTHERS

26 GLOBAL HYPERTENSION MARKET, SWOT AND DBMR ANALYSIS

27 GLOBAL HYPERTENSION MARKET, COMPANY LANDSCAPE

27.1 COMPANY SHARE ANALYSIS: GLOBAL

27.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

27.3 COMPANY SHARE ANALYSIS: EUROPE

27.4 COMPANY SHARE ANALYSIS: ASIA PACIFIC

27.5 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

27.6 MERGERS & ACQUISITIONS

27.7 NEW PRODUCT DEVELOPMENT & APPROVALS

27.8 EXPANSIONS

27.9 REGULATORY CHANGES

27.1 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

28 GLOBAL HYPERTENSION MARKET, COMPANY PROFILE

28.1 MARKETED MANUFACTURE

28.1.1 SANOFI

28.1.1.1. COMPANY OVERVIEW

28.1.1.2. REVENUE ANALYSIS

28.1.1.3. GEOGRAPHIC PRESENCE

28.1.1.4. PRODUCT PORTFOLIO

28.1.1.5. RECENT DEVELOPMENTS

28.1.2 TEVA PHARMACEUTICAL INDUSTRIES LTD.

28.1.2.1. COMPANY OVERVIEW

28.1.2.2. REVENUE ANALYSIS

28.1.2.3. GEOGRAPHIC PRESENCE

28.1.2.4. PRODUCT PORTFOLIO

28.1.2.5. RECENT DEVELOPMENTS

28.1.3 CINCOR PHARMA (ASTRAZENECA)

28.1.3.1. COMPANY OVERVIEW

28.1.3.2. REVENUE ANALYSIS

28.1.3.3. GEOGRAPHIC PRESENCE

28.1.3.4. PRODUCT PORTFOLIO

28.1.3.5. RECENT DEVELOPMENTS

28.1.4 PFIZER INC.

28.1.4.1. COMPANY OVERVIEW

28.1.4.2. REVENUE ANALYSIS

28.1.4.3. GEOGRAPHIC PRESENCE

28.1.4.4. PRODUCT PORTFOLIO

28.1.4.5. RECENT DEVELOPMENTS

28.1.5 MERCK KGAA

28.1.5.1. COMPANY OVERVIEW

28.1.5.2. REVENUE ANALYSIS

28.1.5.3. GEOGRAPHIC PRESENCE

28.1.5.4. PRODUCT PORTFOLIO

28.1.5.5. RECENT DEVELOPMENTS

28.1.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

28.1.6.1. COMPANY OVERVIEW

28.1.6.2. REVENUE ANALYSIS

28.1.6.3. GEOGRAPHIC PRESENCE

28.1.6.4. PRODUCT PORTFOLIO

28.1.6.5. RECENT DEVELOPMENTS

28.1.7 JOHNSON & JOHNSON SERVICES, INC.

28.1.7.1. COMPANY OVERVIEW

28.1.7.2. REVENUE ANALYSIS

28.1.7.3. GEOGRAPHIC PRESENCE

28.1.7.4. PRODUCT PORTFOLIO

28.1.7.5. RECENT DEVELOPMENTS

28.1.8 TAKEDA PHARMACEUTICAL COMPANY LIMITED

28.1.8.1. COMPANY OVERVIEW

28.1.8.2. REVENUE ANALYSIS

28.1.8.3. GEOGRAPHIC PRESENCE

28.1.8.4. PRODUCT PORTFOLIO

28.1.8.5. RECENT DEVELOPMENTS

28.1.9 NOVARTIS AG

28.1.9.1. COMPANY OVERVIEW

28.1.9.2. REVENUE ANALYSIS

28.1.9.3. GEOGRAPHIC PRESENCE

28.1.9.4. PRODUCT PORTFOLIO

28.1.9.5. RECENT DEVELOPMENTS

28.1.10 DAIICHI SANKYO COMPANY, LIMITED

28.1.10.1. COMPANY OVERVIEW

28.1.10.2. REVENUE ANALYSIS

28.1.10.3. GEOGRAPHIC PRESENCE

28.1.10.4. PRODUCT PORTFOLIO

28.1.10.5. RECENT DEVELOPMENTS

28.1.11 BAYER

28.1.11.1. COMPANY OVERVIEW

28.1.11.2. REVENUE ANALYSIS

28.1.11.3. GEOGRAPHIC PRESENCE

28.1.11.4. PRODUCT PORTFOLIO

28.1.11.5. RECENT DEVELOPMENTS

28.1.12 SUN PHARMACEUTICAL INDUSTRIES LTD.

28.1.12.1. COMPANY OVERVIEW

28.1.12.2. REVENUE ANALYSIS

28.1.12.3. GEOGRAPHIC PRESENCE

28.1.12.4. PRODUCT PORTFOLIO

28.1.12.5. RECENT DEVELOPMENTS

28.1.13 ANI PHARMACEUTICALS, INC.

28.1.13.1. COMPANY OVERVIEW

28.1.13.2. GEOGRAPHIC PRESENCE

28.1.13.3. PRODUCT PORTFOLIO

28.1.13.4. RECENT DEVELOPMENTS

28.1.14 ALEMBIC PHARMACEUTICALS LIMITED

28.1.14.1. COMPANY OVERVIEW

28.1.14.2. REVENUE ANALYSIS

28.1.14.3. GEOGRAPHIC PRESENCE

28.1.14.4. PRODUCT PORTFOLIO

28.1.14.5. RECENT DEVELOPMENTS

28.1.15 GILEAD SCIENCES, INC.

28.1.15.1. REVENUE ANALYSIS

28.1.15.2. GEOGRAPHIC PRESENCE

28.1.15.3. PRODUCT PORTFOLIO

28.1.15.4. RECENT DEVELOPMENTS

28.1.16 CHIESI USA, INC.

28.1.16.1. COMPANY OVERVIEW

28.1.16.2. REVENUE ANALYSIS

28.1.16.3. GEOGRAPHIC PRESENCE

28.1.16.4. PRODUCT PORTFOLIO

28.1.16.5. RECENT DEVELOPMENTS

28.1.17 WOCKHARDT

28.1.17.1. COMPANY OVERVIEW

28.1.17.2. REVENUE ANALYSIS

28.1.17.3. GEOGRAPHIC PRESENCE

28.1.17.4. PRODUCT PORTFOLIO

28.1.17.5. RECENT DEVELOPMENTS

28.1.18 ABBVIE.

28.1.18.1. COMPANY OVERVIEW

28.1.18.2. REVENUE ANALYSIS

28.1.18.3. GEOGRAPHIC PRESENCE

28.1.18.4. PRODUCT PORTFOLIO

28.1.18.5. RECENT DEVELOPMENTS

28.1.19 GSK PLC.

28.1.19.1. COMPANY OVERVIEW

28.1.19.2. REVENUE ANALYSIS

28.1.19.3. GEOGRAPHIC PRESENCE

28.1.19.4. PRODUCT PORTFOLIO

28.1.19.5. RECENT DEVELOPMENTS

28.1.20 ZYDUS GROUP

28.1.20.1. COMPANY OVERVIEW

28.1.20.2. REVENUE ANALYSIS

28.1.20.3. GEOGRAPHIC PRESENCE

28.1.20.4. PRODUCT PORTFOLIO

28.1.20.5. RECENT DEVELOPMENTS

28.1.21 CIPLA INC.

28.1.21.1. COMPANY OVERVIEW

28.1.21.2. REVENUE ANALYSIS

28.1.21.3. GEOGRAPHIC PRESENCE

28.1.21.4. PRODUCT PORTFOLIO

28.1.21.5. RECENT DEVELOPMENTS

28.1.22 ELI LILLY AND COMPANY

28.1.22.1. COMPANY OVERVIEW

28.1.22.2. REVENUE ANALYSIS

28.1.22.3. GEOGRAPHIC PRESENCE

28.1.22.4. PRODUCT PORTFOLIO

28.1.22.5. RECENT DEVELOPMENTS

28.2 PIPELINE MANUFACTURE

28.2.1 MINERALYS THERAPEUTICS, INC.

28.2.1.1. COMPANY OVERVIEW

28.2.1.2. REVENUE ANALYSIS

28.2.1.3. GEOGRAPHIC PRESENCE

28.2.1.4. PRODUCT PORTFOLIO

28.2.1.5. RECENT DEVELOPMENTS

28.2.2 ALNYLAM PHARMACEUTICALS, INC.

28.2.2.1. COMPANY OVERVIEW

28.2.2.2. REVENUE ANALYSIS

28.2.2.3. GEOGRAPHIC PRESENCE

28.2.2.4. PRODUCT PORTFOLIO

28.2.2.5. RECENT DEVELOPMENTS

28.2.3 IONIS PHARMACEUTICALS

28.2.3.1. COMPANY OVERVIEW

28.2.3.2. REVENUE ANALYSIS

28.2.3.3. GEOGRAPHIC PRESENCE

28.2.3.4. PRODUCT PORTFOLIO

28.2.3.5. RECENT DEVELOPMENTS

28.2.4 PHARMOSA BIOPHARM INC.

28.2.4.1. COMPANY OVERVIEW

28.2.4.2. REVENUE ANALYSIS

28.2.4.3. GEOGRAPHIC PRESENCE

28.2.4.4. PRODUCT PORTFOLIO

28.2.4.5. RECENT DEVELOPMENTS

28.2.5 AEROVATE THERAPEUTICS, INC.

28.2.5.1. COMPANY OVERVIEW

28.2.5.2. REVENUE ANALYSIS

28.2.5.3. GEOGRAPHIC PRESENCE

28.2.5.4. PRODUCT PORTFOLIO

28.2.5.5. RECENT DEVELOPMENTS

28.2.6 CERENO SCIENTIFIC AB (PUBL)

28.2.6.1. COMPANY OVERVIEW

28.2.6.2. REVENUE ANALYSIS

28.2.6.3. GEOGRAPHIC PRESENCE

28.2.6.4. PRODUCT PORTFOLIO

28.2.6.5. RECENT DEVELOPMENTS

28.2.7 GOSSAMER BIO

28.2.7.1. COMPANY OVERVIEW

28.2.7.2. REVENUE ANALYSIS

28.2.7.3. GEOGRAPHIC PRESENCE

28.2.7.4. PRODUCT PORTFOLIO

28.2.7.5. RECENT DEVELOPMENTS

28.2.8 INSMED INCORPORATED

28.2.8.1. COMPANY OVERVIEW

28.2.8.2. REVENUE ANALYSIS

28.2.8.3. GEOGRAPHIC PRESENCE

28.2.8.4. PRODUCT PORTFOLIO

28.2.8.5. RECENT DEVELOPMENTS

28.2.9 GMAX BIOPHARM

28.2.9.1. COMPANY OVERVIEW

28.2.9.2. REVENUE ANALYSIS

28.2.9.3. GEOGRAPHIC PRESENCE

28.2.9.4. PRODUCT PORTFOLIO

28.2.9.5. RECENT DEVELOPMENTS

28.2.10 AADI BIOSCIENCE

28.2.10.1. COMPANY OVERVIEW

28.2.10.2. REVENUE ANALYSIS

28.2.10.3. GEOGRAPHIC PRESENCE

28.2.10.4. PRODUCT PORTFOLIO

28.2.10.5. RECENT DEVELOPMENTS

28.2.11 OCULAR THERAPEUTIX, INC.

28.2.11.1. COMPANY OVERVIEW

28.2.11.2. REVENUE ANALYSIS

28.2.11.3. GEOGRAPHIC PRESENCE

28.2.11.4. PRODUCT PORTFOLIO

28.2.11.5. RECENT DEVELOPMENTS

28.2.12 QUANTUM GENOMICS

28.2.12.1. COMPANY OVERVIEW

28.2.12.2. REVENUE ANALYSIS

28.2.12.3. GEOGRAPHIC PRESENCE

28.2.12.4. PRODUCT PORTFOLIO

28.2.12.5. RECENT DEVELOPMENTS

29 RELATED REPORTS

30 CONCLUSION

31 QUESTIONNAIRE

32 ABOUT DATA BRIDGE MARKET RESEARCH